Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086976 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
A Phase 3 study of Autoimmune Haemolytic Anaemia, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT07086976 is a Phase 3 study of Autoimmune Haemolytic Anaemia that is actively recruiting participants, run by Sanofi. The registered enrollment target is 90 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT07086976, a Phase 3 study of Autoimmune Haemolytic Anaemia, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA. Following a 4-week screening period, eligible participants will be randomized in a 2:1 ratio to receive rilzabrutinib or placebo in primary analysis period (PAP) for a duration of up to 24 weeks. All participants who completed PAP will then continue in open-label period (OLP) to receive rilzabrutinib for a duration of 28 weeks. Upon the completion of OLP, only participants who demonstrate Hb increase during the last 8 weeks of OLP per specified criteria in the protocol will be eligible to continue in long-term extension (LTE) of the study. The duration of the LTE period will be from the first-participant-in (FPI)-LTE until the last participant completes 52 weeks in LTE. The safety follow-up period of this study following treatment completion or discontinuation will be 2 weeks.
Conditions Studied
Interventions
- DRUG placebo
- DRUG rilzabrutinib
Study Locations (20)
California
- City of Hope National Medical Center- Site Number : 8400023 - Duarte
- USC Norris Comprehensive Cancer Center- Site Number : 8400007 - Los Angeles
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center- Site Number : 8400006 - Torrance
Florida
- Hialeah Hospital- Site Number : 8400009 - Hialeah
- Sylvester Comprehensive Cancer Center- Site Number : 8400031 - Miami
- University Hospital and Medical Center- Site Number : 8400005 - Tamarac
Arizona
- Mayo Clinic in Arizona - Phoenix- Site Number : 8400032 - Phoenix
- Noble Clinical Research- Site Number : 8400003 - Tucson
Michigan
- University of Michigan Health System - Ann Arbor- Site Number : 8400014 - Ann Arbor
- Henry Ford Hospital- Site Number : 8400012 - Detroit
Connecticut
- Yale University School of Medicine- Site Number : 8400027 - New Haven
Minnesota
- Mayo Clinic in Rochester - Minnesota- Site Number : 8400008 - Rochester
New York
- Montefiore Medical Center - Einstein Campus- Site Number : 8400011 - The Bronx
Ohio
- Ohio State University Hospital East- Site Number : 8400020 - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2029-12-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086976
The ClinicalTrials.gov registry entry for NCT07086976 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmune Haemolytic Anaemia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT07086976 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07086976 about?
NCT07086976 is a clinical study titled "A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia". This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIH...
What is the current status of trial NCT07086976?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-08-18. Estimated completion is 2029-12-26.
What conditions does trial NCT07086976 study?
This clinical trial studies the following conditions: Autoimmune Haemolytic Anaemia.
What interventions are being tested in trial NCT07086976?
The interventions under investigation include: placebo (DRUG), rilzabrutinib (DRUG).
Who is sponsoring clinical trial NCT07086976?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07086976 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.